Restoration of Noradrenergic Function in Parkinson's Disease Model Mice

被引:10
|
作者
Cui, Kui [1 ]
Yang, Fan [1 ,2 ]
Tufan, Turan [1 ]
Raza, Muhammad U. [1 ]
Zhan, Yanqiang [1 ,3 ]
Fan, Yan [1 ,4 ]
Zeng, Fei [1 ,3 ]
Brown, Russell W. [1 ]
Price, Jennifer B. [5 ]
Jones, Thomas C. [5 ]
Miller, Gary W. [6 ]
Zhu, Meng-Yang [1 ,7 ]
机构
[1] East Tennessee State Univ, Quillen Coll Med, Dept Biomed Sci, Johnson City, TN 37604 USA
[2] Asia Metropolitan Univ, Hong Kong Inst, Hong Kong, Peoples R China
[3] Wuhan Univ, Dept Neurol, Renmin Hosp, Wuhan, Peoples R China
[4] Nantong Univ, Dept Biochem, Coll Med, Nantong, Peoples R China
[5] East Tennessee State Univ, Dept Biol Sci, Coll Arts & Sci, Johnson City, TN 37604 USA
[6] Columbia Univ, Mailmen Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA
[7] Harvard Med Sch, Karp Family Res Labs, Dept Surg, Boston Childrens Hosp, Boston, MA 02115 USA
来源
ASN NEURO | 2021年 / 13卷
关键词
locus coeruleus; norepinephrine; tyrosine hydroxylase; dopamine; dopamine β -hydroxylase; Morris water maze; DOPAMINE-BETA-HYDROXYLASE; NEUROTROPHIC FACTOR EXPRESSION; REDUCED VESICULAR STORAGE; MORRIS WATER MAZE; NIGRAL CELL LOSS; LOCUS-COERULEUS; TRANSCRIPTION FACTOR; NOREPINEPHRINE TRANSPORTER; GENE-THERAPY; MOUSE MODEL;
D O I
10.1177/17590914211009730
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Dysfunction of the central noradrenergic and dopaminergic systems is the primary neurobiological characteristic of Parkinson's disease (PD). Importantly, neuronal loss in the locus coeruleus (LC) that occurs in early stages of PD may accelerate progressive loss of dopaminergic neurons. Therefore, restoring the activity and function of the deficient noradrenergic system may be an important therapeutic strategy for early PD. In the present study, the lentiviral constructions of transcription factors Phox2a/2b, Hand2 and Gata3, either alone or in combination, were microinjected into the LC region of the PD model VMAT2 Lo mice at 12 and 18 month age. Biochemical analysis showed that microinjection of lentiviral expression cassettes into the LC significantly increased mRNA levels of Phox2a, and Phox2b, which were accompanied by parallel increases of mRNA and proteins of dopamine beta-hydroxylase (DBH) and tyrosine hydroxylase (TH) in the LC. Furthermore, there was considerable enhancement of DBH protein levels in the frontal cortex and hippocampus, as well as enhanced TH protein levels in the striatum and substantia nigra. Moreover, these manipulations profoundly increased norepinephrine and dopamine concentrations in the striatum, which was followed by a remarkable improvement of the spatial memory and locomotor behavior. These results reveal that over-expression of these transcription factors in the LC improves noradrenergic and dopaminergic activities and functions in this rodent model of PD. It provides the necessary groundwork for the development of gene therapies of PD, and expands our understanding of the link between the LC-norepinephrine and dopamine systems during the progression of PD.
引用
收藏
页数:18
相关论文
共 50 条
  • [11] An evidence base for noradrenergic deficits in Parkinson's disease
    Halliday, Glenda
    MOVEMENT DISORDERS, 2012, 27 (13) : 1589 - 1591
  • [12] Establishment of a staging model for Parkinson's disease in mice
    Tian, Yueqin
    Xian, Jianhua
    Tian, Yuehua
    Gao, Xiaoya
    CELLULAR AND MOLECULAR BIOLOGY, 2023, 69 (04) : 141 - 146
  • [13] An Update on Gene Therapy Approaches for Parkinson's Disease: Restoration of Dopaminergic Function
    Van Laar, Amber D.
    Van Laar, Victor S.
    San Sebastian, Waldy
    Merola, Aristide
    Elder, J. Bradley
    Lonser, Russell R.
    Bankiewicz, Krystof S.
    JOURNAL OF PARKINSONS DISEASE, 2021, 11 : S173 - S182
  • [14] GDNF and VMC cotransplantation helps in restoration of neurobehavioral function in Parkinson's disease
    Chaturvedi, R
    Agrawal, AK
    Aziz, MH
    Seth, K
    Khanna, VK
    Seth, PK
    JOURNAL OF NEUROCHEMISTRY, 2002, 81 : 112 - 112
  • [15] Microsleep disturbances are associated with noradrenergic dysfunction in Parkinson's disease
    Doppler, Christopher E. J.
    Smit, Julia A. M.
    Hommelsen, Maximilian
    Seger, Aline
    Horsager, Jacob
    Kinnerup, Martin B.
    Hansen, Allan K.
    Fedorova, Tatyana D.
    Knudsen, Karoline
    Otto, Marit
    Nahimi, Adjmal
    Borghammer, Per
    Sommerauer, Michael
    SLEEP, 2021, 44 (08)
  • [16] Norepinephrine Deficiency in Parkinson's Disease: The Case for Noradrenergic Enhancement
    Espay, Alberto J.
    LeWitt, Peter A.
    Kaufmann, Horacio
    MOVEMENT DISORDERS, 2014, 29 (14) : 1710 - 1719
  • [17] Molecular Imaging of the Noradrenergic System in Idiopathic Parkinson's Disease
    Nahimi, Adjmal
    Kinnerup, Martin B.
    Sommerauer, Michael
    Gjedde, Albert
    Borghammer, Per
    IMAGING IN MOVEMENT DISORDERS: IMAGING METHODOLOGY AND APPLICATIONS IN PARKINSON'S DISEASE, 2018, 141 : 251 - 274
  • [18] Noradrenergic modulation of movement initiation control in Parkinson's disease
    Albares, M.
    Thobois, S.
    Favre, E.
    Broussolle, E.
    Boulinguez, P.
    Ballanger, B.
    MOVEMENT DISORDERS, 2014, 29 : S133 - S134
  • [19] Mice with disrupted mitochondria used to model Parkinson’s disease
    Zak Doric
    Ken Nakamura
    Nature, 2021, 599 (7886) : 558 - 560
  • [20] Protective abilities of ibuprofen in the mice model of Parkinson’s disease
    Maciej Świątkiewicz
    Małgorzata Zaremba
    Ilona Joniec
    Andrzej Członkowski
    Iwona Kurkowska-Jastrzębska
    Pharmacological Reports, 2013, 65 (Suppl 1) : 92 - 93